![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 49, 51218-51225, December 3, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

From the Division of Radiation Research, Department of Radiation Medicine, Lombardi Comprehensive Cancer Canter, Georgetown University School of Medicine, Washington, D. C. 20007
Received for publication, August 12, 2004 , and in revised form, September 1, 2004.
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
HDAC7 is a nuclear encoded Class II HDAC having a conserved C-terminal catalytic domain and a large, highly divergent N-terminal domain implicated in muscle differentiation (10). Cytoplasmic sequestration of HDAC7 can be enhanced by 14-3-3 protein interactions (11) and observed during T cell receptor-mediated apoptosis (8).
Mitochondria were first characterized as intracellular organelles responsible for energy production through the coupling of oxidative phosphorylation to respiration. More recently, mitochondria have been implicated in genetically programmed cell death (12) whereby release of pro-apoptotic mitochondrial inner membrane space factors (13) facilitates the progression of the apoptotic cascade. Dysregulation of the mitochondrial apoptotic program has been linked to both enhanced cell death (14) as well as hyperproliferative growth (15).
Here we describe the novel discovery that the nuclear encoded Class II human histone deacetylase HDAC7 localizes to the mitochondrial inner membrane space (IMS) of several human cell lines, in particular, prostate cancer epithelial cells. Upon induction of the apoptotic cascade, HDAC7 is released from mitochondria and, along with nuclear HDAC7, is redistributed to the cytoplasm. These results highlight a previously unrecognized link between mitochondria, histone deacetylases, and the initiation of apoptosis.
| EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Site-directed MutagenesisHDAC7-R8P site-directed mutagenesis was carried out using Stratagene QuikChange II XL site-directed mutagenesis kit according to the manufacturer's protocol using the following PAGE-purified primers: forward primer, 5'-GGTGGGCCAGCCGCCCCCAGTGG-3'; and reverse primer, 5'-CCACTGGGGGCGGCTGGCCCACC-3'. PCR cycling parameters were as follows: denaturing at 95° C for 50 s, annealing at 60° C for 50 s, and extension for 9 min at 68° C.
Confocal and Non-confocal Immunofluorescent MicroscopyConfocal microscopy was carried out using an Olympus BX61 laser scanning confocal microscope using x60 oil immersion objective with standard lasers and filter sets for fluorescein isothiocyanate and Texas Red analysis. 4',6-diamidino-2-phenylindole (Sigma) staining was used for non-confocal identification of nucleic acid content. Subsequent confocal image acquisition and analysis were carried out using the FluoviewTM software package. Routine non-confocal indirect immunofluorescence was performed on a Nikon E600 microscope according to standard protocols using fluorescein isothiocyanate and Texas Red secondary antibodies (Jackson Immunologicals) and appropriate optical filter sets. Non-confocal image acquisition and analysis was performed using MetaVueTM (version 5.0.3) imaging analysis software (Universal Imaging Corp.).
Computer Amino Acid AnalysisTopPredII and Kyte-Doolittle hydrophobicity plotting and mitochondrial targeting peptide prediction were performed online.2
Cell TransfectionsRoutine Lipofectin (Invitrogen) transfection of GFP-Bax was performed according to the manufacturer's protocols. GFP-HDAC7 stable C4-2 cells were selected for G418 and pooled as mass populations.
Western BlottingProtein samples were run on 1020% gradient SDS-PAGE Tricine minigels (Invitrogen), blotted to nitrocellulose, and blocked in 5% blocking buffer (Bio-Rad). Primary antibodies were added for 1 h at room temperature, washed in 0.1% SDS, Tween. Secondary horseradish peroxidase-conjugated antibodies were added for 1 h at room temperature and washed in 0.1% SDS, Tween. Blots were developed in ECL reagent (Amersham Biosciences) and exposed to film (Amersham Biosciences).
Mitochondria Isolation, Permeabilization, and Subfractionation Mitochondria were isolated from 80% confluent C4-2 cell monolayers using a Pierce mitochondrial isolation kit according to the manufacturer's instructions with the addition of complete EDTA-free protease inhibitor mixture (Roche Applied Science). For permeabilization of the mitochondrial outer membrane (16), cells were plated on glass coverslips for 3 days and then treated with either 0.01 or 0.5% saponin in 4% paraformaldehyde for 30 min at room temperature. Routine indirect immunofluorescence was subsequently carried out using the appropriate primary and secondary fluorescent antibodies.
Mitochondrial subfractionation was carried out on freshly isolated mitochondria. Isolated mitochondria were immediately subfractionated according to protocols established by Greenawalt (17). Briefly, purified mitochondria were resuspended in isolation medium (70 mM sucrose, 220 mM D-mannitol, 2 mM HEPES, 0.5 mg/ml bovine serum albumin adjusted to pH 7.4 with KOH) at a concentration of 100 mg/ml. An equal volume of stock 1.2% digitonin medium was then added and stirred gently on ice for 15 min. Three more volumes of isolation medium were then added and centrifuged at 10,000 x g for 10 min. The sediment consisted of the crude mitoplast (i.e. inner membrane and matrix components) fraction. The supernatant was removed and centrifuged at 144,000 x g for 60 min. Pelleted material contained mitochondrial outer membranes, whereas the remaining fluid consisted largely of soluble inner membrane proteins.
Imaging of Live CellsAll live imaging was carried out using a Nikon TE300 live imaging system with x60 oil immersion objective using MetaMorph 6.1 software (Universal Imaging Corporation). Mito-Tracker Red® was added to culture medium for 30 min according to the manufacturer's protocols.
| RESULTS |
|---|
|
|
|---|
-helix containing clustered positively charged hydrophobic and hydroxylated amino acid residues (21). HDAC7 secondary structure analysis of the N terminus revealed a clustering of basic amino acids commonly observed in amphipathic
-helical structures, including the NAD+-dependent and mitochondrial localized human Class III deacetylase SIRT3 (Fig. 1B).
|
|
Amino acid sequencing predicts an approximate molecular mass of around 100 and 96 kDa for HDAC7a and HDAC7b, respectively. Analysis of HDAC7 protein expression in C4-2 cells consistently failed to identify an HDAC7 species of this size. Suggesting that the majority of HDAC7 in C4-2 cells is proteolytically processed in mitochondria, we routinely observe a truncated form of HDAC7 (
80 kDa) in both C4-2 mitochondrial preparations as well as commercially available heart mitochondrial protein lysates (Fig. 3A).
|
-helix would attenuate mitochondrial import and thus prevent processing of full-length HDAC7. Transient overexpression of C-terminal FLAG-tagged HDAC7 containing the R8P mutation (HDAC7-R8P) in parental C4-2 cells resulted in expression of only unprocessed, full-length HDAC7 (Fig. 3B). As a control, we similarly transfected the HDAC7-R8P mutant into C4-2 cells stably expressing wild type HDAC7-FLAG. Here, both the unprocessed form of HDAC7-R8P (Fig. 3B, upper band) as well as the mitochondrially processed form (Fig. 3B, lower band) of wild type HDAC7 were observed. In sum, we demonstrate that HDAC7 mitochondrial import is dependent upon a structurally intact targeting presequence and that localization of HDAC7 to mitochondria results in proteolytic removal of the targeting presequence. HDAC7 Is a Mitochondrial Inner Membrane Space Protein Undefined cryptic secondary targeting peptides within the mitochondrial targeting presequence dictate which subcompartment will eventually receive a protein. Kyte-Doolittle hydrophobicity plotting and TopPred II software analysis (26) both identify HDAC7 as a relatively hydrophilic protein with no significant regions of hydrophobicity commonly associated with membrane proteins (data not shown). Mitochondrial subfractionation of untreated C4-2 mitochondria reveals that HDAC7 colocalizes with known soluble mitochondrial IMS proteins AIF and Smac/DIABLO (Fig. 4A). Tom20 and the oxidative phosphorylation complex V served as controls for the outer membrane and inner membrane/matrix (e.g. mitoplasts) compartments of mitochondria, respectively.
|
Cytoplasmic Sequestration of HDAC7 under Pro-apoptotic ConditionsSeminal studies of HDAC7 have demonstrated regulated nucleocytoplasmic shuttling resulting in the differentiation of myocytes (11). Cytoplasmic relocalization of HDAC7 has additionally been implicated in thymocyte cell death (8). In light of these reports and our demonstration that HDAC7 can localize to multiple subcellular compartments, including the mitochondrial IMS, we further characterized the translocation dynamics of HDAC7 under pro-apoptotic conditions.
Although still competent for apoptosis as evidenced by GFP-Bax transient overexpression, a variety of known apoptosis agents including Fas-L, LY294002, forskolin, serum starvation, ionizing radiation, and cisplatin failed to readily induce mass apoptosis in these cells as measured by PARP and Bid cleavage as well as H2A.X phosphorylation (data not shown). We demonstrate that a reliable initiator of the apoptotic cascade in C4-2 cells was the aminoglycoside and protein translation inhibitor hygromycin. 48-hour treatment with 100 µg/ml hygromycin readily and reproducibly induced both PARP and Bid cleavage as well as phosphorylation of H2A.X (Fig. 5a).
|
|
| DISCUSSION |
|---|
|
|
|---|
A recent report implicates HDAC7 in thymocyte apoptosis (5). Here, HDAC7 nuclear export during T cell receptor activation derepresses expression of the orphan receptor Nur77 leading to apoptosis. Highlighting a potential pro-apoptotic role of cytoplasmic (or at least non-nuclear) HDAC7, it was further demonstrated that a triple HDAC7 mutant unable to exit the nucleus (and thus unable to enter the cytoplasm) suppressed T cell receptor-mediated apoptosis (5). HDAC7 has been shown to inhibit the expression of Nur77 via the transcription factor MEF2D. Interestingly, the MEF2D binding domain lies in the same N-terminal region of HDAC7 that contains the mitochondrial targeting presequence.
Mitochondrial targeting presequences normally consist of a positively charged motif of 2060 residues, often followed by vaguely defined intramitochondrial sorting peptides. Although not the focus of this study, it seems reasonable to conclude that the presequence does not extend into the NLS as HDAC7 demonstrates nuclear localization. Western blotting of stably transfected GFP-HDAC7 C4-2 cells for GFP detects an
35-kDa band (data not shown). GFP is a 27-kDa protein suggesting that the additional 8 kDa (
70 amino acids) originates from the mitochondrial targeting presequence of HDAC7. These values are entirely compatible with our data. The significance of the N-terminal extensions of mouse and rat HDAC7 is unknown with respect to mitochondrial localization and function. As we routinely observed N-terminally tagged GFP-HDAC7 in the mitochondria of cells, we speculated that N-terminal peptide additions to the targeting presequence may not ultimately affect mitochondrial import. One interesting observation is that whereas we often observed HDAC7 in both the nucleus and cytoplasm of both live and fixed cells, when HDAC7 is localized to mitochondria it is often robust and exclusively mitochondrial. Although the specific cellular condition(s) regulating HDAC7 mitochondrial import are unknown, this observation is likely because of either enhanced HDAC7 mitochondrial import or attenuated release. As 14-3-3 proteins favor cytoplasmic sequestration of phosphorylated HDAC7, and mitochondria are located in the cytoplasm, it is tempting to speculate that kinase activity might ultimately enhance mitochondrial import. Finally, mitochondrially processed HDAC7 is still technically competent for cytonuclear flux as both the NLS and nuclear export sequence remain intact. Indeed, the NLS is now at a more N-terminal site, introducing the concept that mitochondrial processing might be revealing an otherwise masked NLS. This brings up the interesting possibility that mitochondrial processed HDAC7 might have enhanced nuclear import capabilities relative to full-length, unprocessed HDAC7.
We were initially surprised to identify HDAC7 in mitochondria as previous reports have shown dramatic cytoplasmic and nuclear localization of HDAC7. Curiously, whereas we observed occasional nondescript localization of HDAC7 in both the cytoplasm and nucleus of individual cells (Fig. 6), when we did observe mitochondrial HDAC7 in individual cells it was robust and exclusively mitochondrial more often than not. On rare occasions, we observed both punctate mitochondrial localization of GFP-HDAC7 in a background of general cytoplasmic staining (Fig. 2C, top image, lower right GFP-positive cell). Integrating our data into current models of HDAC7 cellular localization, we propose that mitochondrial HDAC7 localization can, at least under certain cellular conditions, be obscured by a more intense general cytoplasmic HDAC7 signal. Furthermore, as the GFP tag was N-terminal in our studies and all known mitochondrial imported proteins had their N-terminal targeting peptide removed via endoproteolytic cleavage, we propose that the cytoplasmic and nuclear GFP-HDAC7 that we observed at no time resided in the mitochondrial inner membrane space. Importantly, this species of HDAC7 is competent to enter mitochondria as the targeting presequence would still be intact. In this model, mitochondria could act as an irreversible intracellular reservoir (at least in non-apoptotic cells) to sequester HDAC7 that would otherwise be available for cytonuclear flux, and this may offer a novel method of epigenetic regulation of the genome. As mitochondrial HDAC7 likely is involved in different biological events relative to unprocessed, full-length HDAC7, we speculate that the repertoire of interacting proteins might be considerably different from those previously reported for non-mitochondrial HDAC7 (10). As HDAC7 is a regulated phosphoprotein and can exist in either cytoplasmic, nuclear, or mitochondrial compartments of individual cells or even the same cell, we conclude that the regulation of HDAC7 intracellular localization is likely quite complex. In sum, we have demonstrated the novel finding that HDAC7 can localize to mitochondria in addition to previous reports demonstrating cytoplasmic and nuclear HDAC7 localization.
As mentioned earlier, mitochondrial release of N-terminally processed HDAC7 and subsequent cytoplasmic sequestration might be directly involved in programmed cell death under apoptotic conditions. Although we readily observed PARP and Bid cleavage as well as H2A.X phosphorylation in response to hygromycin treatment, we routinely failed to observe H2B phosphorylation. H2B phosphorylation has recently been proposed as a definitive marker of commitment to apoptosis (28). Although this marker may eventually become apparent at later time points, under the conditions and time points at which we observed HDAC7 translocation to the cytoplasm, commitment to apoptosis might not be assured.
Taken together, as HDAC7 appears to be the only known HDAC localized to mitochondria, we speculate that HDAC7 has a unique and complex role in normal cellular function, quite possibly apoptosis. Future studies are under way to identify cytoplasmic substrates and further characterize the significance of mitochondrial HDAC7 in the process of programmed cell death.
| FOOTNOTES |
|---|
To whom correspondence should be addressed: Dept. of Radiation Medicine, The Research Bldg., Rm. E-211, Georgetown University School of Medicine, Box 571482, 3970 Reservoir Rd., N.W., Washington, D. C. 20057-1482. Tel.: 202-687-8352; Fax: 202-687-7529; E-mail: jungm{at}georgetown.edu.
1 The abbreviations used are: HDAC, histone deacetylase; IMS, inner membrane space; GFP, green fluorescent protein; FBS, fetal bovine serum; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; AIF, apoptosis-inducing factor; PARP, poly(ADP-ribose) polymerase; NLS, nuclear localization sequence. ![]()
2 R. Bakin and M. Jung, personal communication. ![]()
| ACKNOWLEDGMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. P. Gupta, S. A. Samant, S. H. Smith, and S. G. Shroff HDAC4 and PCAF Bind to Cardiac Sarcomeres and Play a Role in Regulating Myofilament Contractile Activity J. Biol. Chem., April 11, 2008; 283(15): 10135 - 10146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, X. Shi, R. Padmanabhan, Q. Wang, Z. Wu, S. C. Stevenson, M. Hild, D. Garza, and H. Li Identification of novel modulators of mitochondrial function by a genome-wide RNAi screen in Drosophila melanogaster Genome Res., January 1, 2008; 18(1): 123 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Lombard, F. W. Alt, H.-L. Cheng, J. Bunkenborg, R. S. Streeper, R. Mostoslavsky, J. Kim, G. Yancopoulos, D. Valenzuela, A. Murphy, et al. Mammalian Sir2 Homolog SIRT3 Regulates Global Mitochondrial Lysine Acetylation Mol. Cell. Biol., December 15, 2007; 27(24): 8807 - 8814. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lahm, C. Paolini, M. Pallaoro, M. C. Nardi, P. Jones, P. Neddermann, S. Sambucini, M. J. Bottomley, P. Lo Surdo, A. Carfi, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases PNAS, October 30, 2007; 104(44): 17335 - 17340. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, R. B. Klisovic, T. Vukosavljevic, J. Yu, P. Paschka, L. Huynh, J. Pang, P. Neviani, Z. Liu, W. Blum, et al. Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 953 - 960. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Dequiedt, M. Martin, J. Von Blume, D. Vertommen, E. Lecomte, N. Mari, M.-F. Heinen, M. Bachmann, J.-C. Twizere, M. C. Huang, et al. New Role for hPar-1 Kinases EMK and C-TAK1 in Regulating Localization and Activity of Class IIa Histone Deacetylases. Mol. Cell. Biol., October 1, 2006; 26(19): 7086 - 7102. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Kim, J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chie, S. W. Ha, C. I. Park, and G. D. Kao Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 Clin. Cancer Res., February 1, 2006; 12(3): 940 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Basile, R. Mantovani, and C. Imbriano DNA Damage Promotes Histone Deacetylase 4 Nuclear Localization and Repression of G2/M Promoters, via p53 C-terminal Lysines J. Biol. Chem., January 27, 2006; 281(4): 2347 - 2357. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-J. Yang and S. Gregoire Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication Mol. Cell. Biol., April 15, 2005; 25(8): 2873 - 2884. [Full Text] [PDF] |
||||
![]() |
S. Gregoire and X.-J. Yang Association with Class IIa Histone Deacetylases Upregulates the Sumoylation of MEF2 Transcription Factors Mol. Cell. Biol., March 15, 2005; 25(6): 2273 - 2287. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |